Clinical trials: MZL
Leukemia, Lymphoma
Radiolabeled Monoclonal Antibody, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory B-Cell Cancer
RATIONALE: Radiolabeled monoclonal antibodies can locate cancer cells and either kill them or deliver cancer killing substances to them without harming normal cells.
- Trial name
- NCT00004086
- Testing
- filgrastim, cisplatin, cytarabine
- Where
- United States
- Sponsor
- Garden State Cancer Center at the Center for Molecular Medicine and Immunology
Marginal Zone Lymphoma(MZL)
Orelabrutinib Combined With Rituximab ± Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZL
This is a prospective, single-arm, phase II study aimed at evaluating the safety and efficacy of orelabrutinib combined with rituximab ± lenalidomide in response-adapted stratified therapy for untreated marginal zone lymphoma.
- Trial name
- NCT07448324
- Testing
- Orelabrutinib, Rituximab, Lenalidomide
- Where
- China
- Volunteers
- 50 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Indolent Non-hodgkin Lymphoma
IBI376 in Patients With Relapsed or Refractory Follicular Lymphoma/Marginal Zone Lymphoma
A Phase 2, Multicenter, Open-Label Study of IBI376, a PI3Kδ Inhibitor, in Patients with Relapsed or Refractory Follicular Lymphoma/Marginal Zone Lymphoma
- Trial name
- NCT04298879
- Testing
- IBI376
- Where
- China
- Volunteers
- 81 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Follicular Lymphoma and Marginal Zone Lymphoma
MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL)
This phase 1b/2 trial studies the safety and best dose of lenalidomide when given together with MIL62 and how well this combination works in treating patients with Relapsed/Refractory low-grade Follicular Lymphoma(FL) and…
- Trial name
- NCT04110301
- Testing
- Recombinant Humanized Monoclonal Antibody MIL62 Injection, Lenalidomide
- Where
- China
- Volunteers
- 53 people
- Sponsor
- Beijing Mabworks Biotech Co., Ltd.
Marginal Zone Lymphoma, B-cell Lymphoma
Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma
Phase 2, open-label, non-randomized, monotherapy study to evaluate the safety and efficacy of ibrutinib in subject with relapsed/refractory Marginal Zone Lymphoma (MZL).
- Trial name
- NCT01980628
- Testing
- ibrutinib
- Where
- 25 sites in United States, Belgium and 3 more
- Volunteers
- 63 people
- Sponsor
- Pharmacyclics LLC.
Graft Versus Host Disease, Leukemia
Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic Diseases
RATIONALE: Giving chemotherapy, such as fludarabine and cyclophosphamide, and total-body irradiation before a donor umbilical cord blood stem cell transplant helps stop the growth of cancer or abnormal cells and prepares the…
- Conditions
- Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00376519
- Testing
- cyclophosphamide, cyclosporine, fludarabine phosphate
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
CD20 Positive, Chronic Lymphocytic Leukemia
Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant
This phase I trial studies the best dose and how well bendamustine works with standard chemotherapy (fludarabine, rituximab) in treating participants with lymphoid cancers undergoing stem cell transplant.
- Conditions
- CD20 Positive, Chronic Lymphocytic Leukemia, Follicular Lymphoma, Mantle Cell Lymphoma
- Trial name
- NCT00880815
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Anti-Thymocyte Globulin, Bendamustine
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- M.D. Anderson Cancer Center
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
This phase I trial tests zanubrutinib in combination with sonrotoclax for treating underrepresented ethnic and racial minorities with B-cell non-Hodgkin lymphoma that has come back after a period of improvement (relapsed) or that…
- Conditions
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
- Trial name
- NCT06859008
- Testing
- Biopsy, Biospecimen Collection, Bone Marrow Aspiration
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- City of Hope Medical Center
CLL/SLL, NHL
HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL
An open label single-arm clinical trial to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of HMPL-760 in patients with previously treated CLL/SLL or NHL
- Conditions
- CLL/SLL, NHL, MCL, MZL
- Trial name
- NCT05176691
- Testing
- HMPL-760
- Where
- 36 sites in United States, Australia and 5 more
- Sponsor
- Hutchmed
Leukemia, Lymphoma
Ganciclovir Plus Arginine Butyrate in Treating Patients With Cancer or Lymphoproliferative Disorders Associated With the Epstein Barr Virus
RATIONALE: The Epstein Barr virus can cause cancer and lymphoproliferative disorders. Ganciclovir is an antiviral drug that acts against the Epstein Barr virus.
- Conditions
- Leukemia, Lymphoma, Precancerous Condition, Small Intestine Cancer
- Trial name
- NCT00006340
- Testing
- arginine butyrate, ganciclovir
- Where
- 6 sites in United States, France and 2 more
- Sponsor
- Boston Medical Center
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation
This Phase II clinical trial was designed for patients with hematologic malignancies in need of donor peripheral blood stem cell transplant, and have no HLA matched donor.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT01116232
- Testing
- anti-thymocyte globulin, rituximab, sirolimus
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer
RATIONALE: Growth factors, such as palifermin, may prevent chronic graft-versus-host disease caused by donor stem cell transplant.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- NCT01233921
- Testing
- palifermin, flow cytometry, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Martin, Paul
Chronic Myeloproliferative Disorders, Leukemia
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00003406
- Testing
- carboplatin, docetaxel, ifosfamide
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Cancer Treatment Centers of America
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer
This phase II trial studies how well giving fludarabine phosphate, cyclophosphamide, tacrolimus, mycophenolate mofetil and total-body irradiation together with a donor bone marrow transplant works in treating patients with…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- NCT00049504
- Testing
- cyclophosphamide, fludarabine phosphate, tacrolimus
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Fred Hutchinson Cancer Center
Lymphoma
R-CVP for the Treatment of Non-conjunctival Ocular Adnexal MALT Lymphoma (OAML)
The purpose of this study is to determine how efficient the combination of rituximab, cyclophosphamide, vincristine, and prednisolone (R-CVP) is in the treatment of stage I or II non-conjunctival ocular adnexal MALT lymphoma…
- Trial name
- NCT01427114
- Testing
- rituximab, cyclophosphamide, vincristine, and prednisolone
- Where
- 2 sites in South Korea
- Volunteers
- 33 people
- Sponsor
- Konkuk University Medical Center
B-cell Malignancy, Marginal Zone Lymphoma
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Study consists of two main parts to explore tacabrutideg recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a Phase 2 (expansion…
- Conditions
- B-cell Malignancy, Marginal Zone Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma
- Trial name
- CaDAnCe-101 (NCT05006716)
- Testing
- Tacabrutideg
- Where
- 114 sites in United States, Australia and 14 more
- Volunteers
- 689 people
- Sponsor
- BeOne Medicines
Adult Langerhans Cell Histiocytosis, Childhood Langerhans Cell Histiocytosis
Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer
RATIONALE: Giving chemotherapy drugs and total-body irradiation before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Adult Langerhans Cell Histiocytosis, Childhood Langerhans Cell Histiocytosis, Leukemia, Lymphoma
- Trial name
- NCT00008216
- Testing
- Peripheral Blood Stem Cell Transplantation
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Columbia University
Lymphoma
PET Study in Patients With Non-Hodgkin Lymphoma
RATIONALE: Diagnostic procedures, such as fluorine 18-fludeoxyglucose positron emission tomography (PET) scans, may help doctors predict a patient's response to treatment and help plan the best treatment.
- Trial name
- NCT00712556
- Testing
- fluorine 18-fludeoxyglucose positron emission tomography
- Where
- 3 sites in United States
- Volunteers
- 55 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Follicular Lymphoma, Marginal Zone Lymphoma
Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma
BrUOG-401 is a prospective, single-arm, phase 2 trial of first-line therapy in adult patients with previously untreated FL or MZL.
- Conditions
- Follicular Lymphoma, Marginal Zone Lymphoma, B-cell Lymphoma
- Trial name
- NCT04792502
- Testing
- Mosunetuzumab, Lenalidomide
- Where
- 3 sites in United States
- Volunteers
- 52 people
- Sponsor
- Brown University
Breast Cancer, Leukemia
Phase I/II Study of Escalating-Dose Melphalan w/Autologous SCS & Amifostine Cytoprotect
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Conditions
- Breast Cancer, Leukemia, Lymphoma, Neuroblastoma
- Trial name
- NCT00003425
- Testing
- filgrastim, amifostine trihydrate, cyclophosphamide
- Where
- 4 sites in United States
- Volunteers
- 25 people
- Sponsor
- University of Kentucky